Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

NASDAQ:ALZN

Alzamend Neuro, Inc.

Last Close

0.73

18/04 20:00

Market Cap

5.77M

Beta: -

Volume Today

19.90K

Avg: 184.60K

PE Ratio

−0.38

PFCF: −0.69

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics

Please Sign In To Use The Chat